This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Pulmonary Disease, Chronic Obstructive
and you are
over 40
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI).

Provided treatments

  • Drug: GSK573719/GW642444 125/25
  • Drug: GSK573719/GW642444 62.5/25
  • Drug: GSK573719 125
  • Drug: GSK573719 62.5
  • Drug: GW642444 25
  • Device: placebo

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01323660. The sponsor of the trial is GlaxoSmithKline and it is looking for 307 volunteers for the current phase.
Official trial title:
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study B